Articles

Read the work.

Thirty-seven articles since February 2026 on CMC governance, board-level technical risk, and the math of therapies reaching patients — written from inside the searches.

Capital Analysis

The Biotech Capital Report.

A structured ranking of biotech investors by activity, stage, and modality — the same capital intelligence we run inside engagements, made public.

30,486

verified biotech deal events

517

investors ranked for follow-on conviction

Free

cost to you

Read the Biotech Capital Report 2026 →

Portfolio breadth vs follow-on conviction — biotech investors plotted by tier

The Articles

Thirty-seven pieces. One thesis.

That CMC, Quality, and Technical Operations leadership is the most underpriced variable on a biopharma board — and the fastest lever on whether a therapy reaches the people waiting for it.

Read the work.

The Biotech Capital Report.

Thirty-seven pieces. One thesis.

Why Published CRLs Cite Manufacturing

The Hole Always Shows Up in the Middle

CDMO Capstone: Whose Head Holds the Answer

The CTO Mandate Framework: Five Lenses

CDMO 5: Big CDMO, Different Risk

The Series A Board Nobody Upgraded

CDMO 4: Made Under Pressure

Durable: Security of Supply

A Platform Is a Claim. The Machine Makes It True. (Mandate 4: Scalable)

CDMO 3: The Trappings of Growth

What a Diligence Team Opens First (Mandate 3: Acquirable)

CDMO 2: What Do the Fragmentation Numbers Miss?

From “It Worked Once” to “It Works Every Time” (Mandate 2: Reproducible)

Is Our CDMO Industry Model Broken?

Can This Molecule Even Become a Product? (Mandate 1: Possible)

Not All Capital Stays for the Hard Part: Capital and CMC

CMC — The Clark Kent / Diana Prince of the Boardroom

CMC Is a Lever on Exit Multiple. Help to Build the Benchmark that Proves It.

When to Hire What in CMC, and How to Defend It to a Board Counting Every Dollar

Today We Publish the CTO Mandate Framework

Wall Street Is Looking at CMC, Tech Ops & Quality. Here's How To Get Your Board Ready.

CMC Used to Be a Tomorrow Problem. The FDA’s 2026 Trial Reforms Make It a Today Problem.

If Your Acquirer's Diligence Team Has More CMC Expertise Than Your Board, Then Aren’t You Writing Them a Discount?

This Is Why CMC Is the CEO's Greatest Ally...

CMC Leaders Know Which Slide Could Cost 1.28-2.5 Years of Runway. Why Doesn't the Board?

CMC -> The Default Model Is Not the Only Model

I Spent $1,100 to Deeply Learn AI. The Results Left Me Speechless and Falling Back in Love with DISCO.

CMC 2 Board: 4 Lessons to accelerate from TechOps to the Board Table

CMC 2 Board: Are You Ready for the Bully?

Search Engines Killed the Expert. AI Is Killing the Consultant...... Welcome to the Age of the Creative.

CMC Is Not a Cost Center. It Is an Exit Multiplier

No One Is Building the CMC-to-Boardroom Curriculum. So You'll Need to Build It Yourself.

Why it's time for a CMC Voice in the Boardroom...

The most important hire probably isn’t your VP, it's your Directors.

A Bit of a Rant: The AI Gold Rush Is Obsessed With the Wrong Metrics

The CEO’s Capital Problem: Every Dollar Comes With Strings Attached

If Something Feels Off in CMC, It Usually Is...

The framework behind the writing.